Voyager Therapeutics (NASDAQ: VYGR) reported Q3 EPS of ($0.16), $0.29 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $24.63 million versus the consensus estimate of $11.7 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.